Navigation Links
A new genre of diagnostic tests for the era of personalized medicine
Date:7/26/2012

A new genre of medical tests which determine whether a medicine is right for a patient's genes are paving the way for increased use of personalized medicine, according to the cover story in the current edition of Chemical & Engineering News. C&EN is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

Celia Henry Arnaud, C&EN senior editor, points out that the U.S. Food and Drug Administration has approved several precedent-setting cancer drugs that provide a glimpse of the "personalized" medical care that awaits patients with cancer and other diseases in the future. Personalized medicine involves selecting treatments that work best with the set of genes present in each individual person. Such treatments work only for patients with conditions related to mutations, or alterations, in certain genes.

The article describes new "companion diagnostics," or diagnostic tests that already have gone into use, with more on the horizon, to identify patients most likely to benefit from a medication. Doctors must perform these tests before starting treatment. Arnaud describes how pharmaceutical companies are embracing an approach that involves co-development of drugs and companion diagnostics that can be used in clinical trials and later when a medication goes into general use.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
2. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
3. Diagnostic yield of colonoscopy for melena after nondiagnostic upper endoscopy is lower than previously reported
4. Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases
5. Screening for breast cancer without X-rays: Lasers and sound merge in promising diagnostic technique
6. A marker in the lining of the lungs could be useful diagnostic technique for lung cancer screening
7. UGA researchers develop rapid diagnostic test for pathogens, contaminants
8. AMA adopts diagnostic ultrasound utilization and education resolution
9. Physician Groups Call for Fewer Medical Tests
10. URMC clinical trial tests new regimen for hypertension
11. Smell Tests Dont Predict Alzheimers, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Right now, behind ... The agency is hammering out a game plan to implement changes and compromises ... to affect FDA-regulated firms. The new law:, ,     Seeks ways ...
(Date:7/24/2017)... ... 2017 , ... “A Short Walk to the Mailbox”: a remarkable memoir of ... published author, Ed Clark. Ed Clark is a church music director and choral ... minister of music and worship leader for over fifty years. He has a ...
(Date:7/23/2017)... , ... July 23, 2017 , ... A 20-year-long ... St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports ... the disease offers very few benefits. , In the cases involved with this ...
(Date:7/23/2017)... ... July 23, 2017 , ... “I Am Not Nothin’: The Serpent ... who could barely read and write and a brokenhearted young soldier who turned to ... of age novel about the power of simple faith is the work of published ...
(Date:7/22/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 22, ... ... surgeries take place each year with the majority of patients not requiring pain ... American Orthopaedic Society for Sports Medicine’s Annual Meeting today in Toronto, Ontario, ...
Breaking Medicine News(10 mins):
(Date:6/30/2017)... , June 30, 2017  AVACEN Medical (AVACEN) announced the publication ... research describes the use of its AVACEN Treatment Method ... from fibromyalgia. ... AVACEN Medical ... by chronic widespread pain. It affects approximately 200 to 400 million people ...
(Date:6/27/2017)...  Therapix Biosciences Ltd. (Nasdaq: TRPX ) ... development of cannabinoid-based drugs, today announced that the Company ... New York, NY on Wednesday, ... offering (IPO) of American Depository Shares (ADSs) listed on ... Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, ...
(Date:6/20/2017)... and LAGUNA HILLS, Calif. , ... of new data that validate the use of MMprofiler ... patients with multiple myeloma (MM). In a poster presentation ... Hematology Association (EHA) in Madrid, Spain ... MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology: